Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Reinvention Puts Biologics Front And Center

Executive Summary

Through several acquisitions and alliances completed over the last year, Cephalon has patched together a substantial pipeline of biologic drugs, an area of business the specialty pharma is ramping up as it looks to diversify its portfolio beyond wakefulness and pain
Advertisement

Related Content

Cephalon Makes A $130 Mil. Bet On Australian Mesoblast's Stem Cell Technology
Cephalon Makes A $130 Mil. Bet On Mesoblast's Stem Cell Technology
Cephalon's Buchi Steps In To Fill Baldino's Big Shoes
CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol
CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol
Deals Of The Week: Clovis/Clavis; Novartis/Incyte; Jubilant/UAB/SRI ...
"Groupthink" Leads Big Pharma To Downplay Neurosciences At Industry's Peril
"Groupthink" Leads Big Pharma To Downplay Neurosciences At Industry's Peril
Cephalon Lands Option To Buy BioAssets For $30 Mil., Eying Anti-TNFs In Sciatica
Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS051660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel